BeOne Medicines AG
ONC
$315.07
$4.321.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.75% | 39.63% | 48.82% | 48.66% | 52.72% |
| Total Other Revenue | 143.94% | 166.14% | 339.27% | -- | -- |
| Total Revenue | 37.44% | 40.23% | 49.53% | 49.54% | 53.71% |
| Cost of Revenue | 5.77% | 12.53% | 25.89% | 44.16% | 52.40% |
| Gross Profit | 43.11% | 45.34% | 54.17% | 50.49% | 53.94% |
| SG&A Expenses | 16.88% | 13.68% | 17.34% | 20.22% | 17.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.01% | 11.82% | 14.17% | 19.09% | 17.89% |
| Operating Income | 331.93% | 178.69% | 120.99% | 88.35% | 72.52% |
| Income Before Tax | 343.85% | 178.21% | 123.73% | 86.11% | 62.50% |
| Income Tax Expenses | 14.92% | 16.22% | 90.91% | 120.68% | 142.32% |
| Earnings from Continuing Operations | 230.75% | 144.50% | 108.28% | 64.95% | 48.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 230.75% | 144.50% | 108.28% | 64.95% | 48.88% |
| EBIT | 331.93% | 178.69% | 120.99% | 88.35% | 72.52% |
| EBITDA | 781.04% | 244.28% | 145.09% | 110.34% | 87.72% |
| EPS Basic | 225.31% | 142.65% | 107.40% | 65.31% | 49.63% |
| Normalized Basic EPS | 361.96% | 186.24% | 117.30% | 93.45% | 76.11% |
| EPS Diluted | 213.85% | 137.66% | 104.85% | 63.29% | 49.27% |
| Normalized Diluted EPS | 350.72% | 182.90% | 116.39% | 92.89% | 76.04% |
| Average Basic Shares Outstanding | 3.88% | 3.58% | 3.05% | 2.19% | 1.34% |
| Average Diluted Shares Outstanding | 7.05% | 7.72% | 6.10% | 4.22% | 2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -1.66% | -0.82% |